Global Fidaxomicin Market Size, Share & Trends Analysis Report, By Type (Purity: 90%, Purity: 95%, and Others), By Distribution Channel (Hospital Pharmacies and Retail Pharmacies), Forecast (2022-2028)

The global fidaxomicin market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Fidaxomicin is used to treat diarrhoea caused by clostridium difficile in adults and children 6 months of age and older. Fidaxomicin is in a class of medications called macrolide antibiotics. It works by killing bacteria in the intestines. Fidaxomicin comes as a tablet and as a suspension (liquid) to take by mouth. Fidaxomicin will not treat infections in any other part of the body. Antibiotics such as fidaxomicin will not work for colds, flu, or other viral infections. Fidaxomicin has anti-inflammatory and immunological modulatory properties and is used to treat a variety of ailments, including respiratory disorders, soft tissue infections, and sexually transmitted bacterial infections, among others.

Some major players in the market include Biocon Ltd., Astellas Pharma Inc., and Merck & Co Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, In January 2020, FDA approved Merck & Co, Inc. DIFICID (fidaxomicin) to treat clostridioides difficile in children aged six months and older. DIFICID is a macrolide antibacterial medicine intended for adults and pediatric patients aged 6 months and older for treatment of Clostridium Difficile Associated Disease (CDAD). To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by Clostridioides difficile (C. difficile).

DIFICID is contraindicated in patients who have known hypersensitivity to fidaxomicin or any other ingredient in DIFICID. DIFICID should only be used for the treatment of CDAD. DIFICID is not expected to be effective for treatment of other types of infections due to minimal systemic absorption of fidaxomicin. Additionally, in March 2019, the Global Antibiotic Research and Development Collaboration (GARDP) and Evotec AG established a public-private partnership to create first-in-class antibiotics for treating drug-resistant bacterial illnesses.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By  Type
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape– Biocon Ltd., Astellas PharmaInc, and Merck & Co Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Fidaxomicin Market Report by Segment

By Type

• Purity 90%
• Purity 95%

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies

Global Fidaxomicin Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa